These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 34573335)
1. Targeting the CDK6 Dependence of Ph+ Acute Lymphoblastic Leukemia. Porazzi P; De Dominici M; Salvino J; Calabretta B Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573335 [TBL] [Abstract][Full Text] [Related]
2. Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and -independent effects by CDK6-specific PROTACs. De Dominici M; Porazzi P; Xiao Y; Chao A; Tang HY; Kumar G; Fortina P; Spinelli O; Rambaldi A; Peterson LF; Petruk S; Barletta C; Mazo A; Cingolani G; Salvino JM; Calabretta B Blood; 2020 Apr; 135(18):1560-1573. PubMed ID: 32040545 [TBL] [Abstract][Full Text] [Related]
3. Targeting CDK6 and BCL2 Exploits the "MYB Addiction" of Ph De Dominici M; Porazzi P; Soliera AR; Mariani SA; Addya S; Fortina P; Peterson LF; Spinelli O; Rambaldi A; Martinelli G; Ferrari A; Iacobucci I; Calabretta B Cancer Res; 2018 Feb; 78(4):1097-1109. PubMed ID: 29233926 [TBL] [Abstract][Full Text] [Related]
4. CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1 Schneeweiss-Gleixner M; Byrgazov K; Stefanzl G; Berger D; Eisenwort G; Lucini CB; Herndlhofer S; Preuner S; Obrova K; Pusic P; Witzeneder N; Greiner G; Hoermann G; Sperr WR; Lion T; Deininger M; Valent P; Gleixner KV EBioMedicine; 2019 Dec; 50():111-121. PubMed ID: 31761618 [TBL] [Abstract][Full Text] [Related]
5. Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia. Nemoto A; Saida S; Kato I; Kikuchi J; Furukawa Y; Maeda Y; Akahane K; Honna-Oshiro H; Goi K; Kagami K; Kimura S; Sato Y; Okabe S; Niwa A; Watanabe K; Nakahata T; Heike T; Sugita K; Inukai T Mol Cancer Ther; 2016 Jan; 15(1):94-105. PubMed ID: 26637365 [TBL] [Abstract][Full Text] [Related]
6. Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia. Minieri V; De Dominici M; Porazzi P; Mariani SA; Spinelli O; Rambaldi A; Peterson LF; Porcu P; Nevalainen MT; Calabretta B Cancer Res; 2018 Oct; 78(20):5793-5807. PubMed ID: 30154155 [TBL] [Abstract][Full Text] [Related]
7. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1 Mian AA; Haberbosch I; Khamaisie H; Agbarya A; Pietsch L; Eshel E; Najib D; Chiriches C; Ottmann OG; Hantschel O; Biondi RM; Ruthardt M; Mahajna J Ann Hematol; 2021 Aug; 100(8):2023-2029. PubMed ID: 34110462 [TBL] [Abstract][Full Text] [Related]
8. [Comparison of Clinical Outcomes between P190 and P210 Trans-cripts in Adult Ph Chromosome Positive Acute Lymphoblastic Leukemia in the New Era of TKI]. Qiu LL; Lu YJ; Jing Y; Yu L; Liu DH; Wang LL Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):369-74. PubMed ID: 27150994 [TBL] [Abstract][Full Text] [Related]
10. Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition. Xiao X; Liu P; Li D; Xia Z; Wang P; Zhang X; Liu M; Liao L; Jiao B; Ren R J Hematol Oncol; 2020 Jun; 13(1):80. PubMed ID: 32552902 [TBL] [Abstract][Full Text] [Related]
11. The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment. Thomas X; Heiblig M Expert Opin Drug Discov; 2016 Nov; 11(11):1061-1070. PubMed ID: 27548716 [TBL] [Abstract][Full Text] [Related]
12. Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant. Samra B; Kantarjian HM; Sasaki K; Alotaibi AS; Konopleva M; O'Brien S; Ferrajoli A; Garris R; Nunez CA; Kadia TM; Short NJ; Jabbour E Acta Haematol; 2021; 144(3):285-292. PubMed ID: 33238261 [TBL] [Abstract][Full Text] [Related]
13. Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs. Anderson NA; Cryan J; Ahmed A; Dai H; McGonagle GA; Rozier C; Benowitz AB Bioorg Med Chem Lett; 2020 May; 30(9):127106. PubMed ID: 32184044 [TBL] [Abstract][Full Text] [Related]
14. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928 [TBL] [Abstract][Full Text] [Related]
15. Systematic exploration of different E3 ubiquitin ligases: an approach towards potent and selective CDK6 degraders. Steinebach C; Ng YLD; Sosič I; Lee CS; Chen S; Lindner S; Vu LP; Bricelj A; Haschemi R; Monschke M; Steinwarz E; Wagner KG; Bendas G; Luo J; Gütschow M; Krönke J Chem Sci; 2020 Apr; 11(13):3474-3486. PubMed ID: 33133483 [TBL] [Abstract][Full Text] [Related]
16. Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia. Simioni C; Ultimo S; Martelli AM; Zauli G; Milani D; McCubrey JA; Capitani S; Neri LM Oncotarget; 2016 Nov; 7(48):79842-79853. PubMed ID: 27821800 [TBL] [Abstract][Full Text] [Related]
17. Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2. Riva B; De Dominici M; Gnemmi I; Mariani SA; Minassi A; Minieri V; Salomoni P; Canonico PL; Genazzani AA; Calabretta B; Condorelli F Oncotarget; 2016 Dec; 7(49):81555-81570. PubMed ID: 27835591 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute. Kidoguchi K; Ureshino H; Kizuka-Sano H; Yamaguchi K; Katsuya H; Kubota Y; Ando T; Miura M; Takahashi N; Kimura S Int J Hematol; 2021 Aug; 114(2):199-204. PubMed ID: 33907977 [TBL] [Abstract][Full Text] [Related]
19. Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion. Oya S; Morishige S; Ozawa H; Sasaki K; Semba Y; Yamasaki Y; Nakamura T; Aoyama K; Seki R; Mouri F; Osaki K; Miyamoto T; Maeda T; Nagafuji K Int J Hematol; 2021 Feb; 113(2):285-289. PubMed ID: 32951102 [TBL] [Abstract][Full Text] [Related]